OIS-Generic-Author-Image-MALE

Keith Croes

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Pharma

September 22 2021

OIS Retina@ASRS Brings Retina Leaders Together (Again) for Live Meeting in San Antonio

The live and in-person summit showcasing innovation in retina, OIS Retina@ASRS, will be held in San Antonio, Texas, on October 7, a day before the ...
Read More
OIS Summit FDA Approved (2)

September 7 2021

Judy Gordon’s Legacy: Helping Firms Navigate a Path to FDA Approval of Transformative Technology

Judy Gordon, DVM, is not a job-hopper. When Laguna Beach, Calif.-based ClinReg Consulting Services, a company she founded in 1998, announced her retirement in March, ...
Read More
CRISPR and inherited retinal disease

March 18 2020

CRISPR and inherited retinal disease

Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing ...
Read More
AbbVie and Allergan Are Going to Be Just Fine

January 30 2020

AbbVie and Allergan Are Going to Be Just Fine

Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a ...
Read More
Soft CL slows myopia in children

January 22 2020

Soft CL slows myopia in children

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to ...
Read More
Lucentis and Eylea patent expirations in the micro-crystal ball

January 14 2020

Lucentis and Eylea patent expirations in the micro-crystal ball

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018 ...
Read More
RegenxBio sues FDA over clinical hold

November 27 2019

RegenxBio sues FDA over clinical hold

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined ...
Read More
Opthea’s Star Brightens for Stakeholders

October 30 2019

Opthea’s Star Brightens for Stakeholders

It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as ...
Read More
Eyeing Gene Therapy’s Ocular Future

October 9 2019

Eyeing Gene Therapy’s Ocular Future

CHICAGO—The first gene therapy approved in the United States happened to be for an inherited eye disease, with an agent that is administered subretinally. But ...
Read More
Retina Treatment Beyond Protocol

October 2 2019

Retina Treatment Beyond Protocol

CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms ...
Read More
Glaukos' Bid for Avedro: What's Next

August 14 2019

A Closer Look at Glaukos’ Bid for Avedro

Early market reaction to Glaukos Corp.'s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro. ...
Read More
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

July 17 2019

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, ...
Read More